Payment overview · 2025
General Payments
$615.75
5 reported records · 3 companies
Healthcare provider profile · identity verified
Shujing Lin, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BROOKLYN, NY · NPI 1487027496
Verified facts
What the public records show
CMS Open Payments records show Shujing Lin, MD received $615.75 in general payments during 2025 across 5 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 60.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $370.96 | 60.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $125.00 | 20.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $119.79 | 19.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $615.75 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $370.96 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 659 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 475 | 159 |
| Omeprazole | Omeprazole | 406 | 104 |
| Losartan Potassium | Losartan Potassium | 367 | 115 |
| Montelukast Sodium | Montelukast Sodium | 322 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 314 | 76 |
| Fluticasone Propionate | Fluticasone Propionate | 298 | 101 |
| Metformin Hcl | Metformin Hcl | 275 | 90 |
| Alendronate Sodium | Alendronate Sodium | 271 | 82 |
| Finasteride | Finasteride | 198 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 54 |
| Simvastatin | Simvastatin | 175 | 58 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 160 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 160 | 50 |
| Meclizine Hcl | Meclizine Hcl | 151 | 56 |
| Ammonium Lactate | Ammonium Lactate | 147 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 50 |
| Halobetasol Propionate | Halobetasol Propionate | 112 | 55 |
| Azithromycin | Azithromycin | 110 | 84 |
| Januvia | Sitagliptin Phosphate | 109 | 24 |
| Meloxicam | Meloxicam | 109 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 104 | 24 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 99 | 26 |
| Jardiance | Empagliflozin | 93 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 20 |
| Carvedilol | Carvedilol | 77 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 77 | 22 |
| Eliquis | Apixaban | 75 | 14 |
| Naproxen | Naproxen | 69 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 41 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 66 | 19 |
| Incruse Ellipta | Umeclidinium Bromide | 66 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 66 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 16 |
| Allopurinol | Allopurinol | 61 | 17 |
| Bepotastine Besilate | Bepotastine Besilate | 59 | 19 |
| Spironolactone | Spironolactone | 56 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 51 | 14 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | 17 |
| Hydrocortisone | Hydrocortisone | 48 | 18 |
| Mupirocin | Mupirocin | 48 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Azelastine Hcl | Azelastine Hcl | 43 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 16 |
| Lisinopril | Lisinopril | 40 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 40 | suppressed |
| Gabapentin | Gabapentin | 39 | 14 |
| Glipizide Er | Glipizide | 37 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Ibuprofen | Ibuprofen | 33 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Celecoxib | Celecoxib | 31 | 14 |
| Famotidine | Famotidine | 31 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 16 |
| Alcohol Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Loperamide | Loperamide Hcl | 28 | 24 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | 11 |
| Alcohol Swab | Alcohol Antiseptic Pads | 25 | 13 |
| Arnuity Ellipta | Fluticasone Furoate | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Procto-Med Hc | Hydrocortisone | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Prednisone | Prednisone | 17 | 12 |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $615.75 · 5 records | Boehringer Ingelheim Pharmaceuticals, Inc. | FARXIGA, JARDIANCE, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error